{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:57:22Z","timestamp":1792706242754,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"7999","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2024,2,15]]},"DOI":"10.1038\/s41586-024-07018-7","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T12:02:40Z","timestamp":1707307360000},"page":"626-634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["Naturally occurring T cell mutations enhance engineered T cell therapies"],"prefix":"10.1038","volume":"626","author":[{"given":"Julie","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4022-6795","authenticated-orcid":false,"given":"Jay","family":"Daniels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-8565","authenticated-orcid":false,"given":"Yujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-0987","authenticated-orcid":false,"given":"Iowis","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3759-6883","authenticated-orcid":false,"given":"Daniel","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6784-0085","authenticated-orcid":false,"given":"Calvin","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2263-1422","authenticated-orcid":false,"given":"Chlo\u00eb","family":"Thienpont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0406-5840","authenticated-orcid":false,"given":"Camillia","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8300-5071","authenticated-orcid":false,"given":"Garrett","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-7954","authenticated-orcid":false,"given":"Kole T.","family":"Roybal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2379-2226","authenticated-orcid":false,"given":"Jaehyuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"7018_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41573-021-00189-2","volume":"20","author":"AJ Hou","year":"2021","unstructured":"Hou, A. J., Chen, L. C. & Chen, Y. Y. Navigating CAR-T cells through the solid-tumour microenvironment. Nat. Rev. Drug Discov. 20, 531\u2013550 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"7018_CR2","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1038\/ng.3444","volume":"47","author":"L Wang","year":"2015","unstructured":"Wang, L. et al. Genomic profiling of S\u00e9zary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat. Genet. 47, 1426\u20131434 (2015).","journal-title":"Nat. Genet."},{"key":"7018_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"7018_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"7018_CR5","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra2101920","volume":"384","author":"S Mustjoki","year":"2021","unstructured":"Mustjoki, S. & Young, N. S. Somatic mutations in \u201cbenign\u201d disease. N. Engl. J. Med. 384, 2039\u20132052 (2021).","journal-title":"N. Engl. J. Med."},{"key":"7018_CR6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","volume":"127","author":"S Walker","year":"2016","unstructured":"Walker, S. et al. Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome. Blood 127, 948\u2013951 (2016).","journal-title":"Blood"},{"key":"7018_CR7","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1182\/blood-2017-02-768234","volume":"130","author":"J Park","year":"2017","unstructured":"Park, J. et al. Genomic analysis of 220 CTCLs identifies a novel recurrent gain-of-function alteration in RLTPR (p.Q575E). Blood 130, 1430\u20131440 (2017).","journal-title":"Blood"},{"key":"7018_CR8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1182\/blood.2020009655","volume":"138","author":"J Park","year":"2021","unstructured":"Park, J. et al. Integrated genomic analyses of cutaneous T-cell lymphomas reveal the molecular bases for disease heterogeneity. Blood 138, 1225\u20131236 (2021).","journal-title":"Blood"},{"key":"7018_CR9","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.1038\/s41467-020-15572-7","volume":"11","author":"J Daniels","year":"2020","unstructured":"Daniels, J. et al. Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas. Nat. Commun. 11, 1806\u20131806 (2020).","journal-title":"Nat. Commun."},{"key":"7018_CR10","doi-asserted-by":"publisher","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","volume":"367","author":"A Stadtmauer Edward","year":"2020","unstructured":"Stadtmauer Edward, A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science 367, eaba7365 (2020).","journal-title":"Science"},{"key":"7018_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","volume":"558","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307\u2013312 (2018).","journal-title":"Nature"},{"key":"7018_CR12","doi-asserted-by":"crossref","unstructured":"Prinzing, B. et al. Deleting DNMT3A in CAR T cells prevents exhaustion and enhances antitumor activity. Sci. Transl. Med. 13, eabh0272.","DOI":"10.1126\/scitranslmed.abh0272"},{"key":"7018_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.immuni.2015.01.006","volume":"42","author":"GJ Martinez","year":"2015","unstructured":"Martinez, G. J. et al. The transcription factor NFAT promotes exhaustion of activated CD8+ T cells. Immunity 42, 265\u2013278 (2015).","journal-title":"Immunity"},{"key":"7018_CR14","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","volume":"490","author":"R Schmitz","year":"2012","unstructured":"Schmitz, R. et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490, 116\u2013120 (2012).","journal-title":"Nature"},{"key":"7018_CR15","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/ng.3909","volume":"49","author":"Y Liu","year":"2017","unstructured":"Liu, Y. et al. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia. Nat. Genet. 49, 1211\u20131218 (2017).","journal-title":"Nat. Genet."},{"key":"7018_CR16","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"7018_CR17","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41586-022-04494-7","volume":"603","author":"M Legut","year":"2022","unstructured":"Legut, M. et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 603, 728\u2013735 (2022).","journal-title":"Nature"},{"key":"7018_CR18","doi-asserted-by":"publisher","first-page":"eabl6322","DOI":"10.1126\/sciimmunol.abl6322","volume":"7","author":"SM Kahan","year":"2022","unstructured":"Kahan, S. M. et al. Intrinsic IL-2 production by effector CD8 T cells affects IL-2 signaling and promotes fate decisions, stemness, and protection. Sci. Immunol. 7, eabl6322 (2022).","journal-title":"Sci. Immunol."},{"key":"7018_CR19","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41577-018-0087-2","volume":"19","author":"J Ruland","year":"2019","unstructured":"Ruland, J. & Hartjes, L. CARD-BCL-10-MALT1 signalling in protective and pathological immunity. Nat. Rev. Immunol. 19, 118\u2013134 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"7018_CR20","doi-asserted-by":"publisher","first-page":"8338","DOI":"10.1074\/jbc.M116.717322","volume":"291","author":"RP Jattani","year":"2016","unstructured":"Jattani, R. P., Tritapoe, J. M. & Pomerantz, J. L. Intramolecular interactions and regulation of cofactor binding by the four repressive elements in the caspase recruitment domain-containing protein 11 (CARD11) inhibitory domain. J. Biol. Chem. 291, 8338\u20138348 (2016).","journal-title":"J. Biol. Chem."},{"key":"7018_CR21","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.molcel.2018.08.005","volume":"71","author":"JE Burke","year":"2018","unstructured":"Burke, J. E. Structural basis for regulation of phosphoinositide kinases and their involvement in human disease. Mol. Cell 71, 653\u2013673 (2018).","journal-title":"Mol. Cell"},{"key":"7018_CR22","doi-asserted-by":"crossref","unstructured":"Kutzner, K. et al. Phosphorylation of serine-893 in CARD11 suppresses the formation and activity of the CARD11-BCL10-MALT1 complex in T and B cells. Sci. Signal. 15, eabk3083.","DOI":"10.1126\/scisignal.abk3083"},{"key":"7018_CR23","doi-asserted-by":"publisher","first-page":"e42775","DOI":"10.1371\/journal.pone.0042775","volume":"7","author":"S Li","year":"2012","unstructured":"Li, S., Yang, X., Shao, J. & Shen, Y. Structural insights into the assembly of CARMA1 and BCL10. PLoS ONE 7, e42775 (2012).","journal-title":"PLoS ONE"},{"key":"7018_CR24","doi-asserted-by":"publisher","first-page":"794","DOI":"10.15252\/msb.20145968","volume":"11","author":"A Grossmann","year":"2015","unstructured":"Grossmann, A. et al. Phospho-tyrosine dependent protein-protein interaction network. Mol. Syst. Biol. 11, 794 (2015).","journal-title":"Mol. Syst. Biol."},{"key":"7018_CR25","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1084\/jem.20130590","volume":"211","author":"X Fan","year":"2014","unstructured":"Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P. & Allison, J. P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med. 211, 715\u2013725 (2014).","journal-title":"J. Exp. Med."},{"key":"7018_CR26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s40425-019-0827-2","volume":"7","author":"E Massarelli","year":"2019","unstructured":"Massarelli, E. et al. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. J. Immunother. Cancer 7, 351 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"7018_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imcb.1018","volume":"96","author":"M Bardet","year":"2018","unstructured":"Bardet, M. et al. The T-cell fingerprint of MALT1 paracaspase revealed by selective inhibition. Immunol. Cell Biol. 96, 81\u201399 (2018).","journal-title":"Immunol. Cell Biol."},{"key":"7018_CR28","doi-asserted-by":"publisher","first-page":"e1163462","DOI":"10.1080\/2162402X.2016.1163462","volume":"5","author":"T Jiang","year":"2016","unstructured":"Jiang, T., Zhou, C. & Ren, S. Role of IL-2 in cancer immunotherapy. Oncoimmunology 5, e1163462 (2016).","journal-title":"Oncoimmunology"},{"key":"7018_CR29","doi-asserted-by":"publisher","unstructured":"Guedan, S. et al. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. JCI Insight https:\/\/doi.org\/10.1172\/jci.insight.96976 (2018).","DOI":"10.1172\/jci.insight.96976"},{"key":"7018_CR30","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2249.2009.03933.x","volume":"157","author":"MA King","year":"2009","unstructured":"King, M. A. et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 157, 104\u2013118 (2009).","journal-title":"Clin. Exp. Immunol."},{"key":"7018_CR31","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-08-1363","volume":"69","author":"S Bidlingmaier","year":"2009","unstructured":"Bidlingmaier, S. et al. Identification of MCAM\/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma. Cancer Res. 69, 1570\u20131577 (2009).","journal-title":"Cancer Res."},{"key":"7018_CR32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.02.002","volume":"173","author":"Q-X Li","year":"2017","unstructured":"Li, Q.-X., Feuer, G., Ouyang, X. & An, X. Experimental animal modeling for immuno-oncology. Pharmacol. Ther. 173, 34\u201346 (2017).","journal-title":"Pharmacol. Ther."},{"key":"7018_CR33","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-022-04801-2","volume":"607","author":"A Kalbasi","year":"2022","unstructured":"Kalbasi, A. et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 607, 360\u2013365 (2022).","journal-title":"Nature"},{"key":"7018_CR34","doi-asserted-by":"publisher","unstructured":"Overwijk, W. W. & Restifo, N. P. B16 as a mouse model for human melanoma. Curr. Protoc. Immunol. https:\/\/doi.org\/10.1002\/0471142735.im2001s39 (2001).","DOI":"10.1002\/0471142735.im2001s39"},{"key":"7018_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41586-019-1821-z","volume":"576","author":"J Wei","year":"2019","unstructured":"Wei, J. et al. Targeting REGNASE-1 programs long-lived effector T cells for cancer therapy. Nature 576, 471\u2013476 (2019).","journal-title":"Nature"},{"key":"7018_CR36","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner, R. et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. New Engl. J. Med. 386, 2112\u20132119 (2022).","journal-title":"New Engl. J. Med."},{"key":"7018_CR37","doi-asserted-by":"publisher","first-page":"110083","DOI":"10.1016\/j.celrep.2021.110083","volume":"37","author":"H Zhao","year":"2021","unstructured":"Zhao, H. et al. Genome-wide fitness gene identification reveals Roquin as a potent suppressor of CD8 T cell expansion and anti-tumor immunity. Cell Rep. 37, 110083 (2021).","journal-title":"Cell Rep."},{"key":"7018_CR38","unstructured":"FDA investigating serious risk of T-cell malignancy following BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous (28 November 2023)."},{"key":"7018_CR39","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"7018_CR40","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.21971","volume":"107","author":"JD Tward","year":"2006","unstructured":"Tward, J. D., Wendland, M. M., Shrieve, D. C., Szabo, A. & Gaffney, D. K. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 107, 108\u2013115 (2006).","journal-title":"Cancer"},{"key":"7018_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.2020010497","volume":"138","author":"D Chihara","year":"2021","unstructured":"Chihara, D., Dores, G. M., Flowers, C. R. & Morton, L. M. The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma. Blood 138, 785\u2013789 (2021).","journal-title":"Blood"},{"key":"7018_CR42","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1182\/blood-2023-178806","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison, S. J. et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood 142, 6939 (2023).","journal-title":"Blood"},{"key":"7018_CR43","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/j.1365-2141.2006.06158.x","volume":"134","author":"SJ Bowcock","year":"2006","unstructured":"Bowcock, S. J. et al. High incidence of therapy-related myelodysplasia and acute leukaemia in general haematology clinic patients treated with fludarabine and cyclophosphamide for indolent lymphoproliferative disorders. Br. J. Haematol. 134, 242\u2013243 (2006).","journal-title":"Br. J. Haematol."},{"key":"7018_CR44","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.cell.2022.03.023","volume":"185","author":"I Zhu","year":"2022","unstructured":"Zhu, I. et al. Modular design of synthetic receptors for programmed gene regulation in cell therapies. Cell 185, 1431\u20131443 (2022).","journal-title":"Cell"},{"key":"7018_CR45","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2016.01.012","volume":"164","author":"L Morsut","year":"2016","unstructured":"Morsut, L. et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell 164, 780\u2013791 (2016).","journal-title":"Cell"},{"key":"7018_CR46","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"7018_CR47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia. New Engl. J. Med. 365, 725\u2013733 (2011).","journal-title":"New Engl. J. Med."},{"key":"7018_CR48","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jim.2016.01.007","volume":"430","author":"S Jutz","year":"2016","unstructured":"Jutz, S. et al. Assessment of costimulation and coinhibition in a triple parameter T cell reporter line: simultaneous measurement of NF-\u03baB, NFAT and AP-1. J. Immunol. Methods 430, 10\u201320 (2016).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07018-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07018-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T15:04:20Z","timestamp":1709910260000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-024-07018-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":48,"journal-issue":{"issue":"7999","published-print":{"date-parts":[[2024,2,15]]}},"alternative-id":["7018"],"URL":"https:\/\/doi.org\/10.1038\/s41586-024-07018-7","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"20 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.T.R. is a co-founder, consultant, SAB member and stockholder of Arsenal Biosciences and Dispatch Therapeutics. He was a founding scientist and consultant and stockholder in Cell Design Labs, now a Gilead Company. K.T.R. holds stock in Gilead. K.T.R. is an exclusive adviser to Venrock. J.G. and J.D. are founding scientists and stockholders of Moonlight Bio. K.T.R. and J.C. are co-founders and stockholders of Moonlight Bio. K.T.R., J.C., J.G., J.D. and I.Z. are inventors on a University of California, San Francisco and Northwestern University provisional patent for enhancing adoptive T cell therapeutics; 63\/412,300.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}